Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for allergic bronchopulmonary aspergillosis
ACTRN12613000278730Phase 3Completed
- Sponsor
- Melbourne Allergy, Asthma and Immunology Consultants
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of omalizumab in allergic bronchopulmonary aspergillosis (ABPA) (2 arms), sponsored by Melbourne Allergy, Asthma and Immunology Consultants. Primary endpoint: Exacerbations. Started May 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on ACTRN12613000278730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000278730.